A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest^®) for luteal phase support during IVF treatment

Figures & data

Table 1 Progesterone formulation prescription history of audit population (n=100)

Progesterone in the previous IVF cycle	Progesterone in the current IVF cycle			Total
	Progesterone tableta	Progesterone pessaryb	Progesterone capsulec
Progesterone tablet	2	0	1	3
Progesterone pessary	33	1	0	34
Progesterone capsule	1	0	0	1
Progesterone injection	2	0	0	2
Not reported	1	0	0	1
Not applicabled	57	2	0	59
Total	96	3	1	100

Notes:

a 100 mg thrice daily.

b 400 mg twice daily.

c 200 mg thrice daily.

d Patients who did not have a previous IVF cycle.

Abbreviation: IVF, in vitro fertilization.

Figure 1 Patients’ assessment of convenience (A), ease of use (B), and overall experience (C) with using vaginal progesterone tablets (n=96).

Figure 2 Comparison of comfort and convenience between vaginal progesterone formulations by patients who used progesterone tablets during the audit period and have used progesterone pessaries in a previous IVF cycle (n=33).

Abbreviation: IVF, in vitro fertilization.

Figure 3 Patient preference for progesterone formulations among patients who used progesterone tablets during the audit period and have used progesterone pessaries in a previous IVF cycle (n=33).

Abbreviation: IVF, in vitro fertilization.

Figure S1 Questionnaire for women who have been prescribed progesterone for luteal support as part of fertility treatment.